CSO, Xiaokui Zhang, PhD, was recognized Women We Admire's "Top 25 Chief Scientific Officers of 2024."

Our Chief Scientific Officer, Xiaokui Zhang, PhD, was recognized alongside other accomplished leaders in Women We Admire’s “Top 25 Chief Scientific Officers of 2024.”

Congratulations, Xiaokui!

“Dr. Zhang has over 20 years of progressive biopharmaceutical industry experience in research, discovery, and development to advance several research stage programs through IND into clinical development. As CSO at Aspen Neuroscience, Inc., she leads future platform and pipeline development, combining stem cell biology with the latest machine learning and genomic approaches for the autologous iPSC platform company.”

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.